Pfizer Inc. said on May 10 the company will pay $11.6 billion to buy Biohaven Pharmaceutical Holding Co., making a big bet on its ability to boost sales of the top-selling pill in a new class of migraine drugs.
Eisai and Biogen completed the rolling submission of a Biologics License Application for their proposed Alzheimer’s disease drug to the U.S. Food and Drug Administration.
Bruised and battered by its failings with the controversial Alzheimer’s drug Aduhelm, Biogen is looking to right the ship with a new helmsman. The company is on the hunt for a new chief executive officer.
The Parkinson’s Foundation has announced the expansion of PD GENEration: Mapping the Future of Parkinson’s Disease, a first-of-its-kind national initiative offering genetic testing and counseling for people with Parkinson’s disease (PD) at no cost.
AbbVie got off to a strong start for 2022, driven by success from Skyrizi and Rinvoq, as well as the company’s neuroscience platform that includes the company’s depression treatments and its three-pronged approach to migraine.
Cassava Sciences President and CEO Remi Barbier is hitting back at The New York Times, calling out the venerable newspaper for an alleged one-sided article that he claims misrepresented the research of his company by only using sources who were critical of Cassava.
ReutersAxsome Therapeutics said on April 25 the company expects the U.S. health regulator to decline approval for the drug developer’s treatment of acute migraine over unresolved issues of its quality control processes, sending shares of Axsome down 20 percent.
Longitudinal medical and prescription claims were used to assess opioid prescriptions and MME’s dispensed amongst migraine patients nine months prior to and nine months following Nurtec® ODT initiation. Among the 14,019 with migraine who used opioids prior to initiating treatment with Nurtec ODT, approximately 41% had no opioid Rx fills in the 9 months […]
Shares of Cassava Sciences were up more than 5% in premarket trading on February 11 after the U.S. Food and Drug Administration denied a Citizen Petition filed during 2021 on behalf of short-selling clients who sought to suspend the company’s Alzheimer’s clinical trials.
BioSpace looks at the 10 biggest drug approvals of 2021, headlined by Biogen’s Aduhelm (aducanumab) for Alzheimer’s disease and Pfizer and BioNTech’s COVID-19 vaccine Comirnaty.